Prediction of Hepatocellular Carcinoma Recurrence After Curative Treatment by Longitudinal Monitoring MRD Based on ctDNA

This study is looking at whether tracking tiny fragments of tumor DNA in the blood (called circulating tumor DNA, or ctDNA) after surgery for liver cancer (hepatocellular carcinoma) can predict whether the cancer will come back. The goal is to find a better way to monitor patients after curative treatment. **You may be eligible if...** - You are between 18 and 75 years old - You have been diagnosed with liver cancer at an early to intermediate stage that is suitable for curative surgery - Your overall health and liver function meet the study requirements - You have not received prior treatment for this liver cancer **You may NOT be eligible if...** - Your liver cancer is too advanced for curative surgery - You have significant liver disease beyond the cancer itself - Your overall health or blood counts do not meet the required thresholds - You have already received treatment for this liver cancer Talk to your doctor to see if this trial is right for you.